Natural Product (NP) Details

General Information of the NP (ID: NP8426)
Name
Olanzapine
Synonyms
olanzapine; 132539-06-1; Zyprexa; Zyprexa Zydis; Olansek; Zalasta; Zyprexa Intramuscular; Zolafren; Zypadhera; Zyprexa Velotab; LY-170053; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olzapin; Lanzac; Oferta; LY 170053; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; C17H20N4S; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; UNII-N7U69T4SZR; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; LY170053; CHEMBL715; N7U69T4SZR; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; CHEBI:7735; MFCD00866702; olanzapina; NCGC00096077-03; DSSTox_CID_3388; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; DSSTox_RID_77010; DSSTox_GSID_23388; olanzapinum; Olanzapin; Midax; Olanzapine Mylan; 2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine; Olanzapine Teva; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; SMR000466345; Olanzapine Neopharma; CAS-132539-06-1; SR-01000759343; Olanzapine-d8; ALKS-7921; HSDB 8155; Olanzapine [USAN:USP:INN:BAN]; Olanzapine solution; Olanzapine (Zyprexa); KS-1090; ACMC-209wx7; GTPL47; BIDD:PXR0138; SCHEMBL28763; Olanzapine (JAN/USP/INN); US8802672, Olanzapine; MLS000759457; MLS001165781; MLS001195646; MLS001424057; BIDD:GT0332; SCHEMBL117695; SPECTRUM1505024; Olanzapine (LY-170053); DTXSID9023388; Olanzapine, >=98% (HPLC); BDBM35254; BDBM82479; CHEBI:94534; AMY7709; HMS2051H05; HMS2089M04; HMS2093I04; HMS2233F24; HMS3374L02; HMS3393H05; HMS3657I15; HMS3714J03; HMS3743A09; HMS3884J21; ACT03231; ALBB-027265; BCP04917; EBD23216; NSC_4585; ZINC3873830; Tox21_111556; AC-665; ANW-46937; CO0033; NSC754829; NSC801187; s2493; STK634338; STL388024; ZINC52957434; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; AKOS000282888; AKOS005566122; Olanzapine 1.0 mg/ml in Acetonitrile; Tox21_111556_1; ACN-029909; BCP9001021; CCG-100922; CS-1114; DB00334; MCULE-1620364835; NC00172; NSC-754829; NSC-801187; NCGC00096077-01; NCGC00096077-04; NCGC00096077-05; NCGC00096077-06; NCGC00096077-18; NCGC00389791-02; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; HY-14541; I960; SBI-0206786.P001; AB0013948; CAS_132539-06-1; FT-0673219; O0393; SW220248-1; A10667; C07322; D00454; J10363; S-4287; AB00639907-06; AB00639907-07; AB00639907_08; AB00639907_09; 539O061; A806453; L000455; L005958; Q201872; J-006186; SR-01000759343-4; SR-01000759343-6; Z1868057799; Olanzapine, European Pharmacopoeia (EP) Reference Standard; Olanzapine, United States Pharmacopeia (USP) Reference Standard; Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material; (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene; 2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin; Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Lanzac; Zyprexa; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0(3),?]tetradeca-1(14),3(7),5,8,10,12-hexaene; Olanzapine solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material
    Click to Show/Hide
Species Origin Homo sapiens ...     Click to Show/Hide
Homo sapiens
Kingdom: Metazoa
Phylum: Chordata
Class: Mammalia
Order: Primates
Family: Hominidae
Genus: Homo
Species: Homo sapiens
Disease Schizophrenia [ICD-11: 6A20] Approved [1]
Structure
Click to Download Mol
2D MOL

3D MOL

ADMET Property
Absporption
Caco-2 Permeability
 -4.816
 
MDCK Permeability
 -4.801
 
PAMPA
 - - -
 
HIA
 - - -
 
Distribution
VDss
 1.036
 
PPB
 86.6%
 
BBB
 +++
 
Metabolism
CYP1A2 inhibitor
 -
CYP1A2 substrate
 +++
CYP2C19 inhibitor
 - - -
CYP2C19 substrate
 +++
CYP2C9 inhibitor
 - - -
CYP2C9 substrate
 - - -
CYP2D6 inhibitor
 - - -
CYP2D6 substrate
 +++
CYP3A4 inhibitor
 - - -
CYP3A4 substrate
 +++
CYP2B6 inhibitor
 - - -
CYP2B6 substrate
 - - -
CYP2C8 inhibitor
 - - -
HLM Stability
 - - -
 
Excretion
CLplasma
 5.856
 
T1/2
 0.98
Toxicity
DILI
 +++
 
Rat Oral Acute Toxicity
 ++
 
FDAMDD
 ++
 
Respiratory
 +++
 
Human Hepatotoxicity
 +++
 
Ototoxicity
 ++
 
Drug-induced Nephrotoxicity
 +++
 
Drug-induced Neurotoxicity
 +++
 
Hematotoxicity
 +++
 
Genotoxicity
 +++
 
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++). 2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
    Click to Show/Hide
    Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product
Formula
C17H20N4S
PubChem CID
135398745
Canonical SMILES
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C
InChI
1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3
InChIKey
KVWDHTXUZHCGIO-UHFFFAOYSA-N
CAS Number
CAS 132539-06-1
ChEBI ID
CHEBI:7735
TTD Drug ID
D0V4QS
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP
          Fluoxetine      Depression     Click to Show/Hide the Molecular Data of This Drug
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vivo Model Clinical Trial
                    Experimental
                    Result(s)		 Olanzapine/fluoxetine combination demonstrated rapid onset of antidepressant effect (within 7 days) compared to placebo that was sustained over 8 weeks of treatment in a sample of BD patients.
Target and Pathway
Target(s) Dopamine D2 receptor (D2R)  Molecule Info  [3]
KEGG Pathway Rap1 signaling pathway Click to Show/Hide
2 cAMP signaling pathway
3 Neuroactive ligand-receptor interaction
4 Gap junction
5 Dopaminergic synapse
6 Parkinson's disease
7 Cocaine addiction
8 Alcoholism
Panther Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway Click to Show/Hide
2 Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
3 Dopamine receptor mediated signaling pathway
4 Nicotine pharmacodynamics pathway
Reactome Dopamine receptors Click to Show/Hide
2 G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction Click to Show/Hide
2 Monoamine GPCRs
3 GPCRs, Class A Rhodopsin-like
4 Genes and (Common) Pathways Underlying Drug Addiction
5 GPCR ligand binding
6 GPCR downstream signaling
7 Nicotine Activity on Dopaminergic Neurons
References
Reference 1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 47).
Reference 2 Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression. Bipolar Disord. 2007 Sep;9(6):618-27.
Reference 3 Olanzapine: an updated review of its use in the management of schizophrenia. Drugs. 2001;61(1):111-61.
 Download Picture         KEGG Link